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Objective To calculate the cost-effectiveness of implementing PlGF
testing alongside a clinical management algorithm in maternity
services in the UK, compared with current standard care.
Design Cost-effectiveness analysis.
Setting Eleven maternity units participating in the PARROT
stepped-wedge cluster-randomised controlled trial.
Population Women presenting with suspected pre-eclampsia
between 20+0 and 36+6 weeks’ gestation.
Methods Monte Carlo simulation utilising resource use data and
maternal adverse outcomes.
Main outcome measures Cost per maternal adverse outcome
prevented.
Results Clinical care with PlGF testing costs less than current
standard practice and resulted in fewer maternal adverse
outcomes. There is a total cost-saving of UK£149 per patient
tested, when including the cost of the test. This represents a
potential cost-saving of UK£2,891,196 each year across the NHS
in England.
Conclusions Clinical care with PlGF testing is associated with the
potential for cost-savings per participant tested when compared
with current practice via a reduction in outpatient attendances,
and improves maternal outcomes. This economic analysis
supports a role for implementation of PlGF testing in antenatal
services for the assessment of women with suspected pre-
eclampsia.
Keywords Economic analysis, placental growth factor, pre-
eclampsia.
Tweetable abstract Placental growth factor testing for suspected
pre-eclampsia is cost-saving and improves maternal outcomes.
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Introduction
Hypertension in pregnancy affects up to 10% of pregnant
women. Pre-eclampsia complicates 2.8% of singleton preg-
nancies1 and is associated with maternal and perinatal
adverse outcomes.2 In 2012, the cost of pre-eclampsia
within the first 12 months of delivery was US$2.18 billion
in the USA.3
Around 10% of pregnant women will be investigated for
suspected pre-eclampsia, making it among the most com-
mon clinical presentations to obstetric emergency services.
The diagnosis of pre-eclampsia is clinically challenging.
Commonly used methods of investigation such as blood
pressure measurement and proteinuria assessment demon-
strate highly variable test performance.4–6 Ultrasound scan-
ning and maternal admission are costly. Iatrogenic preterm
birth associated with the disease is resource-intensive.7–9 In
prospective observational cohort studies, placental growth
factor (PlGF) <5th centile has good test performance in
assessing women with suspected pre-eclampsia for deter-
mining need for delivery for pre-eclampsia within 14 days
of testing.10 We recently reported in the Placental growth
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factor for the Assessment of hypeRtensive pRegnant
wOmen: a stepped wedge Trial (PARROT) that PlGF test-
ing used alongside a clinical management algorithm
reduced the time to diagnosis of pre-eclampsia from
4.1 days (usual care) to 1.9 days (intervention).11 Where
PlGF was implemented, severe maternal adverse outcomes12
were reduced from 5.4% (24/447; usual care group) to
3.8% (22/573; intervention group), with no evidence of a
difference in gestation at delivery (36.6 versus 36.8 weeks).
National guidelines have approved PlGF testing to rule
out suspected pre-eclampsia in the UK.13 Hypothetical eco-
nomic models have found that PlGF-based testing gives a
cost-saving of between £330 and £103213–15 per woman
tested.16–23 These models have not examined trial data
where use of PlGF has been incorporated into clinical care.
The PARROT trial provides an opportunity to assess the
cost implications of implementing PlGF testing into the
health service with clinical data, and the benefit of a con-
trolled comparison group. The aim of this study was to
conduct a within-trial analysis to calculate the incremental
cost per maternal adverse event prevented associated with
implementing PlGF testing in maternity services in the
National Health Service (NHS) in England, compared with
current standard care.
The use of PlGF testing alongside a clinical management
algorithm may enable clinicians to target resources to those
at greatest need (women testing with a PlGF <100 pg/ml).
This could aid clinical decision making, enabling appropri-
ate risk stratification of care. We anticipated that women
with normal PlGF (>100 pg/ml) could be managed with
less intensive surveillance, providing a cost-saving per
woman tested.13
Methods
This economic evaluation is a within-trial analysis using
data from the PARROT trial and is from an NHS cost per-
spective.
Trial processes
The PARROT study was a multicentre stepped-wedge clus-
ter-randomised controlled trial of PlGF testing alongside a
clinical management algorithm in the assessment of women
with suspected pre-eclampsia. Eleven UK maternity units
(size 3000–9000 deliveries per year) took part. Women
aged 18 years or older were invited to participate in the
trial if they presented to antenatal assessment services with
suspected pre-eclampsia (for example to maternity triage or
the acute obstetric assessment unit) with a live, singleton
fetus between 20+0 weeks and 36 weeks+6 of gestation.
Women with a diagnosis of pre-eclampsia at the time of
clinical presentation were excluded. The maternity units
(clusters) were randomly allocated to the order in which
the intervention (revealed PlGF alongside a clinical man-
agement algorithm) was introduced. At the beginning of
the trial, all units followed ‘usual care’, and every 6 weeks,
a randomly allocated cluster would begin adoption of
revealed PlGF testing. By the end of the trial, all clusters
were recruiting with revealed PlGF testing. The PARROT
trial reported outcomes in over 99% of the participants
enrolled. The trial was approved by the London South East
Research Ethics Committee (ref. 15/LO/2058).
The comparator group and the intervention
Within ‘usual care’, an additional blood sample was col-
lected at enrolment and was processed on an electronically
masked Triage (Alere, San Diego, CA, USA; now Quidel
Cardiovascular Inc., San Diego, CA, USA) instrument
according to the manufacturer’s instructions, so that the
result was recorded but not revealed to the clinical team.
Women were managed by an attending obstetrician follow-
ing local hospital practice based on the NICE guidance on
the Management of Hypertension in Pregnancy.24
Under the intervention conditions (PlGF testing along-
side a management algorithm) women provided a blood
sample which was processed within 4 hours on an
unmasked Triage instrument (Alere, now Quidel Cardio-
vascular Inc.) according to the manufacturer’s instructions.
A result was given to the attending obstetrician to inform
clinical care. The trial was deliberately pragmatic to reflect
how PlGF may be adopted within a healthcare service. No
prescriptive care schedules were recommended following
PlGF testing. The management algorithm provided simple
guidance only, incorporating serum PlGF concentrations
categorised as normal (>100 pg/ml), low (12–100 pg/ml)
or very low (<12 pg/ml) into the national (NICE) guidance
for the Management of Hypertension in Pregnancy (Fig-
ure S1). Women with a serum PlGF concentration of
>100 pg/ml followed a care pathway involving outpatient
management and routine surveillance unless clinical param-
eters such as severe hypertension indicated otherwise.
Those with low PlGF concentrations were advised to ‘in-
crease surveillance’ with a greater frequency of antenatal
care visits and fetal ultrasound scanning. Those with very
low PlGF were ‘assessed as pre-eclampsia’, which included
consideration for admission, intensive monitoring, and fetal
ultrasound scanning.
The primary outcome in the trial was the time, in days,
from presentation with suspected pre-eclampsia to the
woman receiving a documented diagnosis of pre-eclampsia
in the clinical notes. Secondary outcomes included adverse
maternal and perinatal outcomes. Participants were fol-
lowed up from the point of recruitment to the primary
postnatal discharge of the woman and infant pair. All data
were taken from clinical records including handheld notes,
electronic maternity records, and neonatal records.
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Resource use and costs
Resource use data was prespecified. Maternal resource use
included maternity outpatient appointments, antenatal hos-
pital admission, and hospital admission associated with
delivery. This included both standard and intensive care
admissions. Infant resource use included routine care, and
admission to a neonatal unit (special care, high-depen-
dency, and intensive care).25 Information was collected on
mode of delivery based on reference cost categories (spon-
taneous vaginal, assisted delivery, planned caesarean, and
emergency caesarean).26,27 The cost of delivery has been
reported separately as it is included in the NHS Reference
Costs used to calculate the cost per bed day, and hence it
would be double-counting to include this in the Monte
Carlo simulation.
Unit costs were obtained from NHS Reference Costs
2016/201727 and are reported in Table S1. All costs are
weighted, based on the sum of the unit costs for each rele-
vant Healthcare Resource Group multiplied by activity. The
sum of costs is then divided by the sum of the activity to
give a weighted cost per patient based on the frequency of
each Health Care Resource Group. All neonatal admissions
were given the same cost per bed day, as a weighted cost
per bed day derived from the relevant Health Care
Resource Group multiplied by length of stay provides a
closer estimate of total cost then using activity costs based
on ward type.27
The cost of the PlGF test was estimated at £70 per test
2017/2018 (all prices given in Pound Sterling (£) (Quidel,
Cardiovascular Inc.)). We conducted sensitivity analyses
varying the cost of the test between UK£50 and £200.
Effectiveness outcome
Core outcome sets and patient involvement were not rele-
vant to this secondary economic analysis. Quality-adjusted
life years (QALYs) are considered the gold standard effec-
tiveness outcome in economic evaluations.28 The use of
QALYs in economic evaluations of interventions in mater-
nity services presents a number of challenges.29 Patient-re-
ported outcomes were also not collected as part of this
trial, so QALYs calculated using a preference-based mea-
sure of health-related quality of life was not possible.
Instead, effectiveness has been calculated as the mean num-
ber of maternal adverse events avoided per 1000 women
with the intervention compared with current practice. This
was calculated based on the maternal adverse events
reported in the PARROT Trial.11
Statistical analysis
Cost-savings associated with PlGF testing for suspected
pre-eclampsia may differ by PlGF sub-group (normal, low,
and very low), as demonstrated in previous economic
models.19 Cost-savings may also differ based on final diag-
nosis, e.g. pre-eclampsia; gestational hypertension/chronic
hypertension/small for gestational age or none of the
above.19 Each participant was allocated to one of the nine
subgroups groups based on serum PlGF concentration and
final diagnosis. These were included as covariates in each
analysis.
Healthcare resource use was analysed using generalised
linear mixed models (GLMM). Each of the nine categories
was analysed separately to determine the most appropriate
form of general linear model based on the Akaike informa-
tion criterion (AIC). For all models except one, the two-
part negative binomial model was the most appropriate.
This model accounts for the probability that a participant
uses a service, using a count (Poisson) model for values
greater than zero. For neonate intensive care and high
dependency unit (ICU/HDU) admissions, the complex
GLMM would not converge. As a result this was modelled
using logistic regression, and linear regression was used for
length of stay for admitted infants only.
To account for the stepped-wedge cluster-randomised
nature of the trial, all models included fixed effect of linear
time and a random effect for centre.30 Mean adjusted
resource use (with standard errors) were calculated for each
of the nine groups, and by trial allocation. The mean cost
of delivery and 95% confidence intervals by trial allocation
were calculated using a GLMM with log link and family
gamma. All statistical analyses were undertaken using
STATA version 14.2 (StataCorp, College Station, TX, USA)
Probabilistic model
A simple costing analysis of the data does not allow for
exploration of the complex inter-relationship between
PlGF concentration, participant diagnosis, and resource
use. Due to the skewed, over-dispersed nature of the
resource use data, and the fact that these analyses were
not the primary powered end point in the PARROT
trial, it is unlikely that we would find statistically signifi-
cant results, and any significant results would require cir-
cumspect interpretation.31 Instead we have used predicted
adjusted means (and standard errors) and Monte Carlo
simulation to calculate the probability that PlGF testing
is cost-saving compared with current practice for mater-
nal costs, infant costs; delivery costs, and all costs com-
bined. Values used in the model and their distributions
are reported in Tables S2–S8.
Total cost differences between trial arms were calculated
as total costs and as weighted costs. Weighting accounted
for the proportion of participants in each of the nine sub-
groups in each arm of the trial.
The number of adverse events was calculated using a
beta distribution with Monte Carlo simulation for
5000 iterations of the model. The probability that PlGF
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testing was cost-effective compared with current prac-
tice was calculated as willingness to pay per adverse
event avoided, multiplied by the number of adverse
events avoided, minus the total cost per 1000 women
with suspected pre-eclampsia. The probability that
PlGF testing is cost-effective includes the cost of the
PlGF test.
The model was run 5000 times, which was used to gen-
erate the cost-effectiveness acceptability curve (the proba-
bility that PlGF testing is cost-effective for a range of
values of willingness to pay for an adverse event avoided).
The model was developed and run in Microsoft EXCEL
FOR OFFICE 365 (Redmond, WA, USA).
Results
In all, 1005 women were included in the analysis, 434 with
usual care and 571 with clinical care with PlGF testing.
Among all participants, 236 (23.5%) had a PlGF <12 pg/
ml, 385 (38.3%) a PlGF 12–100 pg/ml, and 384 (38.2%)
had a PlGF > 100 pg/ml. There was no contamination
between trial arms (i.e. no duplication of National Health
Service numbers in the trial database).
Participant demographics
Women had a mean age of 31.49 years (SD 5.98 years) and
a mean gestational age of 32–33 weeks’ gestation at trial
entry. In all, 66% of the women were white, 14% were
black, 12% were Asian (Indian, Pakistani, Sri Lankan or
Bangladeshi), 2% were of mixed ethnicity, and 6% were
from Chinese or other ethnic backgrounds. The median
body mass index at booking was 28.4 kg/m2 (IQR 24.2–
34.1). There was a history of pre-eclampsia in a previous
pregnancy in 39%. Full demographics and outcomes have
been reported in the main trial paper.11 The proportion of
women in each diagnostic and PlGF subcategory in the trial
are reported in Figure 1.
Costs
Descriptive statistics and average costs by diagnosis, PlGF
test result, and trial arm allocation compared with current
practice for appointments, length of stay or probability of
admission are reported in Tables S2–S4. Cost differences
(actual and weighted) and the proportion of times clinical
care with PlGF testing costs less than current practice is
reported in Tables 1 and 2. There was no difference in the
cost of delivery between the two groups, with an average
cost of delivery of £3,372 with PlGF testing, (95% CI
£3,258 to £3,484) and an average cost of £3,318 with usual
care (95% CI £3,187 to £3,450).
Outpatient appointments had lower costs for all sub-
groups, with 100% of iterations of the model being cost-
saving with PlGF testing. Maternal inpatient admission
costs were greater with PlGF testing. This was mostly due
to increased costs for women with a final pre-eclampsia
diagnosis from appropriate management. Overall there was
a reduction in costs for women admitted to intensive or
high-dependency care (£86 weighted cost saving per
woman, in 78.74% of iterations) and infant neonatal
admissions, although with lower certainty (£71 weighted
cost saving per infant in 50.4% of iterations).
Overall, the average weighted cost-saving per woman
with PlGF testing was £147 in 66.6% of iterations. For
women and infants combined, the average weighted cost-
saving with PlGF testing was £149 per woman in 55.5% of
iterations of the model, when accounting for a PlGF test
cost of £70. Without accounting for the cost of PlGF test-
ing, the average weighted cost saving per woman tested was
£219 in 59.9% of iterations. Table 3 presents the probabil-
ity that PlGF testing is cost-saving for a range of PlGF test-
ing prices.
Cost-effectiveness
Clinical care with PlGF testing resulted in an average of 15
fewer maternal adverse events per 1000 women tested com-
pared with usual care. PlGF testing dominated usual care
in that it cost less and resulted in fewer maternal adverse
events. There is a 72% probability that the intervention is
cost-effective at a £20,000 willingness to pay for an adverse
event prevented (see Figure S2).
Discussion
Main findings
The use of PlGF testing for suspected preterm pre-
eclampsia has a 59.9% probability of representing a cost-
saving compared with current practice, with a total cost-
saving of £149 per woman when including the cost of
the test (in this instance, Triage PlGF at £70 per test).
Given that there were 646 794 births in England in
2017,32 10% of pregnant women have suspected pre-
eclampsia, and 30% of these present before 37 weeks’
gestation, PlGF testing could be performed in approxi-
mately 38 800 pregnant women per year. This would
result in a potential cost saving of £2,891,196 each year
across the English NHS. The majority of cost-savings
associated with PlGF testing are through a reduction seen
in maternal outpatient appointments in women testing
with a PlGF >100 pg/ml. Our resource use data suggest
that where PlGF testing is implemented, high-risk women
(for example those with low or very low PlGF) are more
appropriately managed, as shown by the increased ante-
natal inpatient costs in these groups. With different com-
mercial assay prices, the magnitude of the cost savings
will depend on the cost per test. PlGF testing results in
fewer maternal adverse events for a lower cost than usual
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care, i.e. PlGF testing dominates usual care, and hence
no incremental cost per adverse event prevented is
reported.
Strengths and limitations
The strengths of this study are in the direct comparison of
resource use between women undergoing PlGF testing
against women with usual care using trial data. The trial
included NHS maternity units participating from across the
UK, with prospective recruitment of an ethnically and
socio-demographically varied group of participants,
enabling generalisability to the broader NHS setting.
Our analysis evaluates the impact that clinical decisions
have on resource use following PlGF testing as compared
with usual care. We report the cost-savings and maternal
adverse events averted. Usually a cost per adverse event
reported should be avoided due to double-counting:
adverse events are included in both the costs and the effec-
tiveness estimate. However, within our trial we did not
include resource use assessment beyond the primary post-
natal discharge of the mother and infant pair. We therefore
did not capture any ongoing costs associated with maternal
adverse events. In the PARROT trial there were five serious
adverse events with usual care (two eclamptic fits, two
strokes, and one cardiac arrest in four women) compared
with no such corresponding events with PlGF testing. It
was not possible to include community rehabilitation costs
or resource use associated with ongoing medical manage-
ment and readmissions. We were unable to assess health-
related quality of life and wellbeing scores, and any impact
on loss of earnings associated with these serious adverse
events, which may be significant. Our estimated cost-saving
is therefore likely to be a conservative estimate.
Interpretation
In this study, we have shown a modest cost-saving in com-
parison with other studies.16,17,19–23 Previous health eco-
nomic studies of the implementation of PlGF testing in
clinical care were based on hypothetical assumptions of
reduction in resource use, with greater cost-savings than
we have presented in this analysis. Current ‘usual care’
relies upon imperfect stratification of pregnancies with sus-
pected pre-eclampsia by obstetricians causing resource-in-
tensive investigation of women. PlGF testing enables more
appropriate stratification, targeting resource use to where it
is more clinically appropriate. The conservative cost-saving
Figure 1. Proportion of women in each diagnostic and PlGF category in the PARROT trial. CHT, chronic hypertension; GH, gestational hypertension;
SGA, small for gestational age.
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presented in our analysis is due to a redistribution in
maternity and neonatal resource use with PlGF testing,
rather than an overall reduction in resource use that was
anticipated by hypothetical models.
The PARROT trial evaluated PlGF testing in women pre-
senting with suspected pre-eclampsia. The PARROT trial
did not assess indications for or frequency of repeat PlGF
testing. There is currently no mandate for repeated PlGF
testing outside of research settings but it may impact fur-
ther on maternal and perinatal outcomes, and subsequently
on health resource use. The optimum frequency of repeated
PlGF measurement remains uncertain but is likely that
repeat sampling will impact on costs associated with the
implementation of PlGF testing. This could be both in the
cost of additional tests and in cost-savings associated with
better stratification of care and avoidance of further mor-
bidity.
Conclusion
Clinical care with PlGF testing is cost-saving, and is asso-
ciated with reduced numbers of maternal adverse events
compared with usual care. Given that PlGF testing has
also been shown to be associated with an improvement in
the time to diagnosis of pre-eclampsia,11 this analysis sup-
ports a role for implementation of PlGF in antenatal ser-
vices for the assessment of women with suspected pre-
eclampsia.
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Table 3. Probability that PlGF plus management algorithm is cost-
saving for a range of costs per PlGF test. All prices given in GBP (£)
Cost per
PlGF test
Probability
cost-saving—
Maternal
costs only
Probability
cost-saving—
Infant costs only
Probability
cost-saving—
Maternal and
Infant costs
£50 60.7% 46.6% 56.9%
£100 55.3% 42.2% 53.5%
£150 49.5% 38.2% 50.0%
£200 43.6% 34.4% 46.7%
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